Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Norway won’t give Oxford-AstraZeneca vaccine to over 65s

MHRA assures UK vaccine recipients that jab is safe for all adults

Bethany Dawson
Thursday 04 February 2021 14:04 EST
Comments
Germany’s vaccine committee has reportedly said it will only recommend the AstraZeneca/Oxford coronavirus vaccine for under-65s
Germany’s vaccine committee has reportedly said it will only recommend the AstraZeneca/Oxford coronavirus vaccine for under-65s (Dado Ruvic/Reuters)

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Norway will not offer the AstraZeneca vaccine against Covid-19 to individuals over the age of 65, the Norwegian Institute of Public Health (FHI) said on Thursday, making it the latest European country to restrict its use.

Roughly 135,000 individuals in Norway have received their first coronavirus vaccine, with 35,000 having received their second jab, from vaccines made by Moderna and Pfizer, the agency said

However, the FHI has said it will not be administering AstraZeneca's Covid vaccine to people in older age groups, suggesting the smaller number of participants above the age of 65 in the trial conducted by the British-Swedish drug maker.

This move follows that of health officials in France, Germany, Italy, Sweden and Poland, who have advised against its use for those over the age of 65, citing a lack of data on its efficacy in older people. 

However, these concerns have been disputed by some, with Dr June Raine, the UK Medicines and Healthcare products Regulatory Agency (MHRA) chief executive, saying: "Current evidence does not suggest any lack of protection against Covid-19 in people aged 65 or over who receive the Covid-19 vaccine AstraZeneca.

"The data we have show that the vaccine produces a strong immune response in the over-65s, and that it is safe," she added. 

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in